Amarin Corporation plc

Equities

AMRN

US0231112063

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-06-06 pm EDT 5-day change 1st Jan Change
0.7048 USD -0.45% Intraday chart for Amarin Corporation plc -16.13% -18.99%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tech Firms Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading MT
Sector Update: Health Care Stocks Rise Late Afternoon MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon MT
Sector Update: Health Care MT
Amarin Shares Fall After CEO Resignation MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
Amarin Names Aaron Berg as Chief Executive Officer MT
Amarin Corporation plc Announces CEO Changes CI
Amarin Corporation plc Announces Executive Changes CI
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading MT
Amarin Says Greece Approves Vazkepa for National Reimbursement; Signs Commercialization Agreement With Vianex MT
Amarin Corporation plc Receives National Reimbursement for Vazkepa (Icosapent Ethyl) in Greece by Greek Ministry of Health CI
Amarin Corporation plc Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A CI
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3% MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading MT
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading MT
Transcript : Amarin Corporation plc, Q1 2024 Earnings Call, May 01, 2024
Earnings Flash (AMRN) AMARIN CORPORATION Posts Q1 Revenue $56.5M MT
Amarin Corporation plc announces an Equity Buyback for $50 million worth of its shares. CI
Amarin Corporation plc Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Amarin Corporation plc authorizes a Buyback Plan. CI
Chart Amarin Corporation plc
More charts
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
0.708 USD
Average target price
1 USD
Spread / Average Target
+41.24%
Consensus
  1. Stock Market
  2. Equities
  3. AMRN Stock
  4. News Amarin Corporation plc
  5. Earnings Flash (AMRN) AMARIN CORPORATION Posts Q1 Revenue $56.5M